




Table 1. Characteristics of c-Rel inhibitor compounds

| | M.W. | Structure | IC50, EMSA | Tumor cell growth inhibition <i>in vitro</i> ^a (IC50) | Optimum conc. for <i>in vitro</i> T-cell treatment | Duration of inhibitory effect ^b | Plasma half-life ^c |
|---------------|--------|---|------------|--|--|--|-------------------------------|
| Dexamethasone | 392.46 |  | N/A | > 20μM | | | |
| DHMEQ | 261.23 |  | 40μM | 7μM | | | |
| IT-603 | 329.16 |  | 3μM | 18μM | 20μM for 24 hrs | < 96 hrs | 2.25 hrs |

^a Human diffuse large B-cell lymphoma (DLBCL) cell line Ly3 was used.

^b CD5⁺ splenocytes were treated with IT-603 for 24 hours and transferred to lethally irradiated recipients. Analysis of c-Rel activity was performed by flow cytometry.

^c Plasma samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at various time points after 12 mg/kg intraperitoneal injection of IT-603.

DHMEQ, dehydroxymethylepoxyquinomicin; M.W., molecular weight; IUPAC, International Union of Pure and Applied Chemistry; IC50, inhibitory concentration 50; conc., concentration; N/A, not applicable.

Table 2. Roles of c-Rel in T-cell responses and transplantation immunology

| | c-Rel^{-/-} mice (steady state/autoimmune/infection) | Reference # | GVHD^a (c-Rel ^{-/-} or inhibitor treated donor T-cells) |
|--------------------------------------|--|--------------------|--|
| Th1 | defective~normal | #12, #13 | decreased |
| Th2 | normal | #12, #13 | increased |
| Th17 | defective | #12, #19 | no change |
| nTreg | defective | #14, #15, #16, #17 | increased |
| iTreg | defective | #17 | increased |
| Graft survival | prolonged | #31, #32 | N/A |
| GVHD survival | prolonged (donor T-cells) | #10 | prolonged |
| IL-2 | defective (<i>in vitro</i>) | #7, #8 | increased |
| T _E /T _N ratio | decreased (<i>in vitro</i>) | #7, #8 | decreased |
| T-cell activation | defective (<i>in vitro</i>) | #7, #8 | decreased |
| T-cell proliferation | defective (<i>in vitro</i>) | #7, #8 | decreased |

nTreg, natural Treg; iTreg, induced Treg; T_N, naïve T cells; T_E, effector T cells; N/A, not applicable.

^a Summary of our findings.